Treatment with dupilumab led to significant reductions in sinus opacification, nasal congestion and nasal polyps in patients with allergic fungal rhinosinusitis. Dupilumab, an interleukin-4 receptor ...

How prevalent are fungal infections in the differential diagnosis of chronic sinusitis?—JANICE SKINNER, CRNP, Sykesville, Md. Fungal sinus infections occur primarily in immunosuppressed patients and ...

Priority Review approval extends dupilumab into AFRS with prior surgery, expanding sino-nasal indications beyond CRSwNP and representing the ninth FDA-approved indication across type 2 inflammatory ...

What Is Dupixent, and Why Does It Matter? Dupixent (dupilumab) is a prescription medicine for treating various allergic conditions and is given as a shot under the skin. The FDA has now approved ...

The FDA approval of the biologic drug Dupixent for allergic fungal rhinosinusitis may help patients living with this challenging condition and help them avoid repeat surgeries. The U.S. Food and Drug ...

Researchers from the University of Alabama at Birmingham published work in Modern Pathology highlighting six cases of chronic granulomatous fungal sinusitis. The article, titled “Histopathologic ...

Please provide your email address to receive an email when new articles are posted on . The FDA based dupilumab’s approval on results from the LIBERTY-AFRS-AIMS trial. This marks the first treatment ...

Approval covers adults and children ≥6 years with prior sinonasal surgery, representing the first FDA-cleared pharmacologic option specifically for AFRS and dupilumab’s ninth U.S. indication.

The U.S. Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for the treatment of adult and pediatric patients aged 6 years and older with allergic fungal rhinosinusitis (AFRS) with a ...

The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult and pediatric patients aged 6 years and older with allergic fungal rhinosinusitis (AFRS) and a ...